Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2

To combat the COVID-19 pandemic, vaccines against SARS-CoV-2 are now given to protect populations worldwide. The level of neutralizing antibodies following the vaccination will evolve with time and vary between individuals. Immunoassays quantifying immunoglobulins against the viral spike (S) protein...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexandre Marchand, Ingrid Roulland, Florian Semence, Olof Beck, Magnus Ericsson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	vaccination against SARS-CoV-2 neutralizing antibodies detection quantitative dried blood spots plasma immune status Science Q
Acceso en línea:	https://doaj.org/article/4ac2fde2baf942edacfcaa7bb3458462
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ac2fde2baf942edacfcaa7bb3458462
record_format	dspace
spelling	oai:doaj.org-article:4ac2fde2baf942edacfcaa7bb34584622021-11-25T18:10:29ZUse of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-210.3390/life111111252075-1729https://doaj.org/article/4ac2fde2baf942edacfcaa7bb34584622021-10-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1125https://doaj.org/toc/2075-1729To combat the COVID-19 pandemic, vaccines against SARS-CoV-2 are now given to protect populations worldwide. The level of neutralizing antibodies following the vaccination will evolve with time and vary between individuals. Immunoassays quantifying immunoglobulins against the viral spike (S) protein in serum/plasma have been developed, but the need for venous blood samples could limit the frequency and scale of control in populations. The use of a quantitative dried blood spot (DBS) that can be self-collected would simplify this monitoring. The objective of this study was to determine whether a quantitative DBS device (Capitainer qDBS 10 µL) could be used in combination with an Elecsys anti-SARS-CoV-2 S immunoassay from Roche to follow the development and persistence of anti-S antibodies. This objective was carried out through two clinical studies. The first study investigated 14 volunteers who received two doses of the Comirnaty (Pfizer) vaccine. The levels of anti-S antibodies and the progression over time post-vaccination were studied for three months. The level of produced antibodies varied between subjects, but a similar trend was observed. The anti-S antibodies were highly stimulated by the second dose (×100) and peaked two weeks later. The antibody levels subsequently decreased and three months later were down to 65%. DBS proved to be sufficiently sensitive for use in evaluating the immune status against SARS-CoV-2 over a prolonged time. The second cohort was composed of 200 random patients from a clinical chemistry department in Stockholm. In this cohort, we had no information on previous COVID-19 infections or vaccination. Nevertheless, 87% of the subjects had anti-S immunoglobulins over 0.8 U/mL, and the bias between plasma and DBS proved to be variable, as was also seen in the first vaccination study.Alexandre MarchandIngrid RoullandFlorian SemenceOlof BeckMagnus EricssonMDPI AGarticlevaccination against SARS-CoV-2neutralizing antibodies detectionquantitative dried blood spotsplasmaimmune statusScienceQENLife, Vol 11, Iss 1125, p 1125 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vaccination against SARS-CoV-2 neutralizing antibodies detection quantitative dried blood spots plasma immune status Science Q
spellingShingle	vaccination against SARS-CoV-2 neutralizing antibodies detection quantitative dried blood spots plasma immune status Science Q Alexandre Marchand Ingrid Roulland Florian Semence Olof Beck Magnus Ericsson Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
description	To combat the COVID-19 pandemic, vaccines against SARS-CoV-2 are now given to protect populations worldwide. The level of neutralizing antibodies following the vaccination will evolve with time and vary between individuals. Immunoassays quantifying immunoglobulins against the viral spike (S) protein in serum/plasma have been developed, but the need for venous blood samples could limit the frequency and scale of control in populations. The use of a quantitative dried blood spot (DBS) that can be self-collected would simplify this monitoring. The objective of this study was to determine whether a quantitative DBS device (Capitainer qDBS 10 µL) could be used in combination with an Elecsys anti-SARS-CoV-2 S immunoassay from Roche to follow the development and persistence of anti-S antibodies. This objective was carried out through two clinical studies. The first study investigated 14 volunteers who received two doses of the Comirnaty (Pfizer) vaccine. The levels of anti-S antibodies and the progression over time post-vaccination were studied for three months. The level of produced antibodies varied between subjects, but a similar trend was observed. The anti-S antibodies were highly stimulated by the second dose (×100) and peaked two weeks later. The antibody levels subsequently decreased and three months later were down to 65%. DBS proved to be sufficiently sensitive for use in evaluating the immune status against SARS-CoV-2 over a prolonged time. The second cohort was composed of 200 random patients from a clinical chemistry department in Stockholm. In this cohort, we had no information on previous COVID-19 infections or vaccination. Nevertheless, 87% of the subjects had anti-S immunoglobulins over 0.8 U/mL, and the bias between plasma and DBS proved to be variable, as was also seen in the first vaccination study.
format	article
author	Alexandre Marchand Ingrid Roulland Florian Semence Olof Beck Magnus Ericsson
author_facet	Alexandre Marchand Ingrid Roulland Florian Semence Olof Beck Magnus Ericsson
author_sort	Alexandre Marchand
title	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
title_short	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
title_full	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
title_fullStr	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
title_full_unstemmed	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2
title_sort	use of quantitative dried blood spots to evaluate the post-vaccination level of neutralizing antibodies against sars-cov-2
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4ac2fde2baf942edacfcaa7bb3458462
work_keys_str_mv	AT alexandremarchand useofquantitativedriedbloodspotstoevaluatethepostvaccinationlevelofneutralizingantibodiesagainstsarscov2 AT ingridroulland useofquantitativedriedbloodspotstoevaluatethepostvaccinationlevelofneutralizingantibodiesagainstsarscov2 AT floriansemence useofquantitativedriedbloodspotstoevaluatethepostvaccinationlevelofneutralizingantibodiesagainstsarscov2 AT olofbeck useofquantitativedriedbloodspotstoevaluatethepostvaccinationlevelofneutralizingantibodiesagainstsarscov2 AT magnusericsson useofquantitativedriedbloodspotstoevaluatethepostvaccinationlevelofneutralizingantibodiesagainstsarscov2
_version_	1718411496302575616

Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2

Ejemplares similares